On Wednesday, Jones Trading adjusted its outlook on Curis (NASDAQ:CRIS), a biotechnology company, by reducing its price target to $18.00 from the previous $27.00. Despite the decrease, the firm maintained its Buy rating on the stock.
The revision reflects a new valuation based on a sum-of-the-parts (SOTP) net present value (NPV) and price-to-earnings (PE) analysis. This analysis suggests an approximate $250 million probability-adjusted peak sales for the company's drugs in 2033, with a 14% probability of success (POS) and a 12% discount rate applied.
The key components contributing to the price target in their NPV model include CA-4948, Curis's drug for relapsed/refractory acute myeloid leukemia (r/r AML), valued at $1 per share. Additionally, the treatment for relapsed/refractory primary central nervous system lymphoma (r/r PCNSL) adds $0.35 per share, with cash holdings and technology contributing $14 per share to the valuation.
The analyst highlighted several risks that could affect Curis's future performance and valuation. These risks encompass potential clinical trial failures, the drug's efficacy being limited to certain patient types, and challenges in expanding the drug development pipeline. Furthermore, there are concerns about safety at high dose levels, the necessity to demonstrate survival benefits, the ability to secure an accelerated approval path for their drugs, and the pressure from competitive products in the market.
Curis's stock price target reflects a complex landscape of drug development, where success hinges on navigating clinical, regulatory, and competitive challenges.
InvestingPro Insights
Following the recent outlook adjustment by Jones Trading on Curis (NASDAQ:CRIS), it's worth considering additional insights that could inform investors' perspectives. With a current market capitalization of approximately $92.48 million, Curis exhibits certain financial characteristics that are noteworthy. The company's Price / Book ratio, standing at 9.77 as of the last twelve months up to Q1 2024, indicates a high valuation relative to the company's book value. Despite facing challenges, Curis's stock has experienced a significant 176.72% price uptick over the last six months, showcasing a strong return in the short term.
On the operational front, analysts have revised their earnings upwards for the upcoming period, reflecting a degree of optimism about the company's prospects. However, Curis's gross profit margins remain weak, with gross profit at -29.92 million USD, translating to a gross profit margin of -304.92%. This underlines the financial challenges the company is facing, particularly as analysts do not anticipate Curis will be profitable this year.
Investors considering Curis as a potential addition to their portfolio should note that the company does not pay a dividend, which may be a factor for those seeking income-generating investments. For those seeking more in-depth analysis, InvestingPro offers additional tips and insights on Curis. Utilize the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription, and discover the 9 additional InvestingPro Tips available at InvestingPro.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.